Apomorphine
Movapo, APO-go
- Dosage form
- Tablet
- Available strengths
- 10 mg/mL
- Drug class
- Non-ergot dopamine agonist (antiparkinsonian rescue agent)
- Common brand
- Movapo, APO-go
Clinical overview. Apomorphine is a rapid-onset, short-acting injectable dopamine agonist used as rescue therapy for acute "off" episodes in advanced Parkinson disease that have not responded to adjustment of other medications. Treatment starts with a supervised test dose with blood pressure monitoring, requires antiemetic (domperidone) pretreatment since 5-HT3 antagonists are contraindicated with it, and carries the class-wide dopamine agonist risks of orthostatic hypotension, sudden sleep episodes, and impulse control disorders. It is for subcutaneous injection only -- intravenous administration causes crystallization and a real pulmonary embolism risk.
Indication
Common therapeutic uses
- Acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in advanced Parkinson disease that have not been adequately controlled by adjusting other Parkinson medications.
- Studied only as an intermittent subcutaneous injection given as an adjunct to existing oral or transdermal Parkinson therapy, not as monotherapy.
- Must never be given intravenously -- this is not an alternate route, it is a distinct and dangerous error (see Serious side effects).
Pregnancy
Risk assessment and monitoring considerations
- There are no adequate, well-controlled studies of apomorphine in pregnant women; it was teratogenic in rabbits and embryolethal in rats at clinically relevant doses in animal studies. Use in pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus.
Breastfeeding
Infant exposure considerations
- It is not known whether apomorphine passes into human breast milk. Because many drugs are excreted in breast milk and harm to a nursing infant cannot be excluded, breastfeeding is not recommended during apomorphine treatment.
Geriatrics
Dosing and tolerability considerations
- More than half of patients in the apomorphine clinical development program were 65 years of age or older; confusion, hallucinations, falls, cardiovascular events, and treatment discontinuation for adverse effects were all more common in this group. Titrate as in younger adults, but with closer monitoring for these effects.
Pediatrics
Use in children and adolescents
- Safety and efficacy have not been established in patients under 18 years of age; apomorphine is not recommended in this population.
Dosage & Administration
Practical dosing and administration
- Subcutaneous injection only -- never intravenous. Express every prescribed dose in mL, not mg, to avoid confusion between the two units.
- Start an antiemetic (domperidone) at least 2 days before the first apomorphine dose and continue it for as long as apomorphine is used, since apomorphine causes significant nausea/vomiting on its own; reassess periodically whether domperidone is still needed rather than continuing it indefinitely by default.
- Give the first dose only as a 0.2 mL (2 mg) test dose, in a setting where a healthcare professional can measure supine and standing blood pressure and pulse before dosing and at 20, 40, and 60 minutes after (longer if hypotension persists at 60 minutes); a patient who develops clinically significant orthostatic hypotension on this test dose is not a candidate for apomorphine.
- If the 0.2 mL (2 mg) test dose is tolerated and effective, continue 0.2 mL (2 mg) PRN for recurring off-episodes; increase in 0.1 mL (1 mg) increments every few days as an outpatient if needed.
- If the 0.2 mL (2 mg) test dose is tolerated but not effective, a supervised 0.4 mL (4 mg) test dose may be given at least 2 hours later at the next off-episode; if tolerated and effective, the outpatient maintenance dose becomes 0.3 mL (3 mg) PRN, titrated in 0.1 mL increments as needed.
- Maximum single dose 0.6 mL (6 mg); wait at least 2 hours between doses; maximum 5 doses per day; maximum total daily dose 2 mL (20 mg). Doses above 0.6 mL did not show additional benefit in trials.
- If a given dose fails to relieve a specific off-episode, do not give a second dose for that same episode -- wait for the next off-period instead.
- Rotate the injection site (abdomen, thigh, or upper arm) with every injection to reduce injection-site reactions, and inspect the solution before use -- do not use it if discoloured (it should be colourless), cloudy, or contains visible particles; a solution that has turned green indicates oxidation and must be discarded.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Expected effects reflect exaggerated dopaminergic stimulation: nausea, vomiting, abnormal movements, hallucinations, agitation, and hypotension.
- There is no specific antidote. A phenothiazine or similar antipsychotic may be considered for severe central stimulation, though its effectiveness for this purpose is unproven; management is otherwise supportive (IV fluids, cardiac monitoring).
Common side effects
Frequently reported tolerability concerns
- Nausea or vomiting may occur, especially at treatment initiation before an effective antiemetic dose is established.
- Yawning may occur.
- Drowsiness or dizziness may occur.
- Injection-site reactions -- bruising, nodules or granulomas, itching -- occur in roughly a quarter of patients; rotating the injection site reduces this risk.
- Rhinorrhea may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Sudden onset of sleep during normal daytime activities, including while driving, which can occur without any warning drowsiness and is not limited to treatment initiation.
- Orthostatic hypotension, most pronounced during dose escalation -- adds to the fall risk from Parkinson disease's own postural instability (falls occurred in about 30% of clinical trial patients, with about 5% considered serious).
- Confusion and hallucinations, more frequent in patients 65 years of age and older.
- Impulse control disorders -- pathological gambling, hypersexuality, compulsive shopping, or binge eating -- a class effect of dopamine agonists that patients often do not recognize as abnormal themselves; ask directly rather than waiting for the patient to volunteer it.
- Profound hypotension and loss of consciousness when combined with a 5-HT3 antagonist (ondansetron, granisetron, palonosetron) -- this combination is contraindicated, not just cautioned against.
- Intravenous administration causes crystallization of apomorphine in the vein, leading to thrombus formation and pulmonary embolism -- apomorphine must only ever be given subcutaneously.
- Seek urgent medical attention for fainting, chest pain, a high fever with muscle rigidity, or a sudden sleep episode while driving or operating machinery.
Use with caution
Situations requiring closer assessment
- Cardiovascular disease -- dopamine agonists including apomorphine cause dose-related drops in blood pressure.
- Non-severe hepatic or renal impairment (apomorphine is contraindicated outright in severe impairment -- see Contraindications).
- A history of psychotic illness -- apomorphine can worsen psychosis.
- Sulfite sensitivity -- the ampoule formulation contains sodium metabisulfite and the pen formulation contains sodium bisulfite, both of which can cause allergic-type reactions, including anaphylaxis and asthma exacerbation, in susceptible people, particularly those with asthma.
- Alcohol -- potentiates apomorphine's hypotensive and sedating effects; advise against alcohol use during treatment.
Contraindications
Situations where therapy may be inappropriate
- Known hypersensitivity to apomorphine or to any ingredient, including the sulfite excipients.
- Concomitant use of a 5-HT3 antagonist (ondansetron, granisetron, palonosetron) -- risk of profound hypotension and loss of consciousness.
- Concomitant use of antihypertensive medications or vasodilators -- the hypotensive effect of apomorphine may be significantly potentiated.
- Severe hepatic impairment or severe renal impairment.
Drug interactions
Clinically relevant combinations
- 5-HT3 antagonists (ondansetron, granisetron, palonosetron): contraindicated -- profound hypotension and loss of consciousness.
- Antihypertensives and vasodilators: contraindicated -- additive hypotension.
- Other CNS depressants and alcohol: additive sedation and hypotension.
- Other dopaminergic Parkinson medications: apomorphine is typically added on top of existing therapy, so review the full regimen for additive dopaminergic adverse effects (dyskinesia, hallucinations) whenever apomorphine is added.
Food interactions
Meal-related administration
- Not applicable -- parenteral formulation.
Time of administration
Practical scheduling
- Given as needed at the onset of an "off" episode, not on a fixed schedule. The first dose and any dose increase must be given under medical supervision with blood pressure/pulse monitoring, but a caregiver or the patient may give subsequent stable-dose injections once a healthcare professional determines it is appropriate.
Storage
Product handling
- Store per the product-specific storage conditions on the pen or ampoule labelling; protect from light.
- Do not use if the solution is discoloured, cloudy, or contains particles -- a green discolouration indicates oxidation and that dose must be discarded.
- Ampoules are for single use only; discard any unused portion.
Patient take-away
Key counselling points for a quick closing summary
- This medicine is a rescue injection for sudden "off" periods, not a medicine taken on a fixed daily schedule.
- Your first dose and any dose increase must be given by, or directly supervised by, a healthcare professional who will check your blood pressure lying down and standing up.
- Never inject this medicine into a vein -- it is for injection just under the skin only.
- You must take an anti-nausea medicine (domperidone) starting a few days before your first dose, and must never combine this medicine with ondansetron or similar anti-nausea medicines.
- Tell your doctor right away if you or your family notice new urges to gamble, shop, eat, or have sex more than usual -- these can happen with this medicine and you may not notice them yourself.
- Do not drive or use machinery if you feel drowsy, since sudden sleep episodes can happen without any warning.
- Rotate the injection site each time and check the liquid before injecting -- do not use it if it looks cloudy, has particles, or has turned green or another colour.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.